Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Drukarch

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
European Journal of Pharmacology|March 26, 1991
Beta-adrenoceptor-sensitive adenylate cyclase is inhibited by activation of mu-opioid receptors in rat striatal neuronsB J Van Vliet, S R Ruuls, B Drukarch, et al.
Neuroscience Letters|June 2, 1995
Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal developmentC H Langeveld, C A Jongenelen, E Schepens, et al.
Behavioural Pharmacology|April 26, 2000
The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297G Andringa, R J Vermeulen, B Drukarch, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1994
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeysR J Vermeulen, B Drukarch, M C Sahadat, et al.
European Journal of Pharmacology|April 22, 1993
The selective dopamine D1 receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeysR J Vermeulen, B Drukarch, M C Sahadat, et al.
European Journal of Pharmacology|September 2, 1987
9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ currentB Drukarch, K S Kits, E G Van der Meer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosisG Tissingh, H W Berendse, P Bergmans, et al.
European Journal of Pharmacology|September 15, 1994
Dopamine D1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytesR J Vermeulen, C A Jongenelen, C H Langeveld, et al.
Experimental Brain Research|January 1, 1995
Repeated administration of a selective dopamine D2 receptor agonist to 6-OHDA-lesioned rats does not affect the survival and outgrowth of intrastriatal fetal mesencephalic graftsF L Van Muiswinkel, J G Bol, J M Ruijter, et al.
Acta Neurologica Scandinavica|December 1, 1991
Cyclandelate in diabetic neuropathy. A double-blind, placebo-controlled, randomized, cross-over studyJ J Heimans, B Drukarch, I Matthaei, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
European Journal of Pharmacology|March 26, 1991
Beta-adrenoceptor-sensitive adenylate cyclase is inhibited by activation of mu-opioid receptors in rat striatal neuronsB J Van Vliet, S R Ruuls, B Drukarch, et al.
Neuroscience Letters|June 2, 1995
Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal developmentC H Langeveld, C A Jongenelen, E Schepens, et al.
Behavioural Pharmacology|April 26, 2000
The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297G Andringa, R J Vermeulen, B Drukarch, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1994
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeysR J Vermeulen, B Drukarch, M C Sahadat, et al.
European Journal of Pharmacology|April 22, 1993
The selective dopamine D1 receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeysR J Vermeulen, B Drukarch, M C Sahadat, et al.
European Journal of Pharmacology|September 2, 1987
9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ currentB Drukarch, K S Kits, E G Van der Meer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosisG Tissingh, H W Berendse, P Bergmans, et al.
European Journal of Pharmacology|September 15, 1994
Dopamine D1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytesR J Vermeulen, C A Jongenelen, C H Langeveld, et al.
Experimental Brain Research|January 1, 1995
Repeated administration of a selective dopamine D2 receptor agonist to 6-OHDA-lesioned rats does not affect the survival and outgrowth of intrastriatal fetal mesencephalic graftsF L Van Muiswinkel, J G Bol, J M Ruijter, et al.
Acta Neurologica Scandinavica|December 1, 1991
Cyclandelate in diabetic neuropathy. A double-blind, placebo-controlled, randomized, cross-over studyJ J Heimans, B Drukarch, I Matthaei, et al.
Pageof 6